As GSK jettisons consumer brands, smaller marketer sees boon

Share this article:
As GSK jettisons consumer brands, smaller marketer sees boon
As GSK jettisons consumer brands, smaller marketer sees boon

GlaxoSmithKline divested North American OTC drugs worth about $200 million in sales, a portfolio that seemed like a good strategic fit for buyer Prestige Brands Holdings.

The 17 OTC brands, which do not include weight-loss product Alli, were sold for £426 million ($660 million) in cash to US-based Prestige. The products spanned primarily the adult analgesic (BC, Goody's, Ecotrin), gastrointestinal (Beano, Gaviscon, Tagamet), ear-wax relief (Debrox) and sleep-aid (Sominex) categories.

It was a bittersweet sale for GSK. Prestige's purchase price for the North American brands amounted to more than three times sales, but cash was reduced by taxes and transaction costs. GSK will receive net cash proceeds of only £242 million ($375 million), observed JP Morgan analyst Alexandra Hauber in an investor note.

Moreover, the drugmaker would have preferred to unload a much bigger consumer portfolio to one buyer. Other largely European-based brands with another $600 million in sales, including Alli, await a buyer.

GSK is looking to focus on consumer brands in oral health, wellness/OTC and nutrition like Sensodyne, Panadol and Horlicks, while jettisoning others. The firm, which announced its intention to divest the non-core consumer assets in late 2010, has not disclosed the total number of brands on the block.

For Prestige, a US marketer of over-the-counter drug and household cleaning products, the buy complements a healthcare lineup whose major brands include Chloraseptic, Clear Eyes and Compound W.

The GSK acquisition, coming on the heels of recent acquisitions of five brands from Blacksmith Brands and Dramamine from Johnson & Johnson over the past year, gave the smaller marketer platforms to compete in two new categories—adult aspirin-based analgesics and gastrointestinal—while also adding scale.

“Following the completion of the [GSK] transaction, Prestige's top 10 brands will average sales of $35 million (compared with $20 million a year ago),” William Blair analyst Jon Andersen told investors.

That heft may enable the company to better support investment in innovation and marketing. “At a minimum,” Andersen added, “we expect Prestige to line-extend the brands and provide additional marketing support, both of which could breathe additional life into the acquired products.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.